Van Cleef Asset Management Inc Buys 3,299 Shares of Bristol-Myers Squibb (NYSE:BMY)

Van Cleef Asset Management Inc grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 23.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 17,576 shares of the biopharmaceutical company’s stock after purchasing an additional 3,299 shares during the quarter. Van Cleef Asset Management Inc’s holdings in Bristol-Myers Squibb were worth $902,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Bristol-Myers Squibb by 91.7% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,207,453 shares of the biopharmaceutical company’s stock worth $61,954,000 after purchasing an additional 577,428 shares during the last quarter. Syon Capital LLC grew its stake in shares of Bristol-Myers Squibb by 95.9% in the fourth quarter. Syon Capital LLC now owns 13,425 shares of the biopharmaceutical company’s stock worth $689,000 after purchasing an additional 6,573 shares during the last quarter. Eley Financial Management Inc grew its stake in shares of Bristol-Myers Squibb by 1.5% in the fourth quarter. Eley Financial Management Inc now owns 37,431 shares of the biopharmaceutical company’s stock worth $1,921,000 after purchasing an additional 554 shares during the last quarter. Disciplined Equity Management Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $132,000. Finally, Community Bank N.A. grew its stake in shares of Bristol-Myers Squibb by 2.0% in the fourth quarter. Community Bank N.A. now owns 211,655 shares of the biopharmaceutical company’s stock worth $10,860,000 after purchasing an additional 4,217 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Wells Fargo & Company raised their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded down $4.18 during mid-day trading on Thursday, hitting $44.68. The stock had a trading volume of 45,047,382 shares, compared to its average volume of 15,901,512. The firm has a market capitalization of $90.56 billion, a P/E ratio of 11.70, a P/E/G ratio of 1.48 and a beta of 0.39. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The firm’s 50 day moving average is $51.22 and its 200 day moving average is $51.31. Bristol-Myers Squibb has a one year low of $44.37 and a one year high of $69.74.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The business’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.37%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.